AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00887276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)~1. 20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes~2. 20 ml physiologic saline solution (placebo) (over 30 min)~3. 20 ml physiologic saline solution (placebo) (over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo~2. 2 capsules Placebo~3. 2 capsules Placebo~Total time of the therapy:at least 7 days, but at most 10 days
Study NCT00887276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin;Amoxicillin
Description: intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)~1. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)~2. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~3. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 2 capsules Amoxicillin (0,5 g)~2. 2 capsules Amoxicillin (0,5 g)~3. 2 capsules Amoxicillin (0,5 g)~Total time of the therapy: at least 7 days, but at most 10 days
Study NCT03437395 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Balloon Brachytherapy
Description: The balloon brachytherapy catheter method uses one tube with a small balloon on the end placed where the tumor had been. The balloon is filled with salt water so it fits this space. The end of the tube will extend from the side of the breast and will be connected to a special machine for treatments. The RT dose is delivered by a radioactive seed that travels through the tube into the center of the balloon. The seed will be removed at the end of each treatment. The tube and the balloon filled with salt water will stay in the breast until the 10 RT treatments are done. The radiation oncologist will decide if this type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10-15 minutes.
Study NCT03437395 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 3D Conformal External Beam Irradiation
Description: 3D conformal external beam irradiation uses a beam of radiation to deliver the radiation therapy dose to the place in the breast where the cancer was removed. The Radiation Oncologist will decide which type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10 to 15 minutes.
Study NCT03187990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]PSMA-11
Description: PET/MRI with \[68Ga\]PSMA will be compared to mpMRI for biopsy guidance.
Study NCT03187990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PSMA-1007
Description: 18F-PSMA-1007 PET/CT for biopsy guidance and intraoperative target verification.
Study NCT01404377 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: infiltration with ropivacaine solution
Description: Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
Study NCT00212498 — intervention group
Intervention type: PROCEDURE
Intervention: Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies
Description: Blood sample
Study NCT02839343 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02839343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT02839343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV
Study NCT02839343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: oxaliplatin IV, leucovorin IV and 5-FU IV
Study NCT04785131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prune
Description: daily consumption of 50 grams prune.
Study NCT01576822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: This protocol will utilize a sauna as the primary method of detoxification.
Description: This study is a randomized, 2-arm, dose-finding safety and feasibility trial. After screening, informed consent and randomization, participants will complete a medically-monitored sauna-based detoxification program.~High Dose Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna).~Low Dose Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna).
Study NCT03675152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft spinal brace
Description: Soft thoracolumbar brace worn 23 hours a day.
Study NCT03675152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thoracolumbar orthosis
Description: Hard thoracolumbar orthosis done individually molded, Worn 23 hours a day.
Study NCT03675152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Excersice restriction
Description: Patients are only allowed to do isometrical excersices adviced by a physiotherapist.
Study NCT03675152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Excersice restriction
Description: Patients are only allowed to do isometrical excersices adviced by a physiotherapist.
Study NCT02000414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraperitoneal daptomycin
Description: intraperitoneal daptomycin administartion and study of daptomycin kinetics
Study NCT00897897 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Philips MRI-guided HIFU system
Description: HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
Study NCT02989142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INTER-ACT
Description: Pre-conception coaching sessions: We encourage less motivated women to participate to the trial by collaborating with Kind \& Gezin from the very beginning, as most timepoints of the counselling sessions coincide with the time points of the Kind\&Gezin vaccine scheme (postpartum week 6, week 8, week 12, 6 months). We will organize the coaching in a mother and baby friendly community-based setting or in the hospitals, as preferred by the mothers.~Pregnancy coaching sessions: take place in hospital, at the time of the three planned ultrasound scans.~By consequence, the applied methodology can be applied as such at the moment of global utilisation in Flanders.
Study NCT02511509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bifrontal electroconvulsive therapy
Description: The centre of each electrode will be placed 4-5 cm above the outer canthus of the eye along a vertical line perpendicular to a line connecting the pupils.
Study NCT02511509 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bitemporal electroconvulsive therapy
Description: The centre of the stimulus electrodes will be applied 2-3 cm above the midpoint of the line connecting the outer canthus of the eye and the external auditory meatus on each side of the individual's head.
Study NCT01478620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canephron® N
Description: 3x 2 coated tablets/day for 7 days p.o.
Study NCT00249821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen®
Description: Saizen® \[somatropin (recombinant deoxyribonucleic acid \[rDNA\] origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Study NCT00249821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen®
Description: Saizen® \[somatropin (rDNA origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Study NCT00640978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 30 mg orally weekly for 4 weeks
Study NCT00640978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily for 28 Days
Study NCT02117583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fasting conditions
Study NCT02117583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fed conditions
Study NCT02117583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fasting conditions
Study NCT02117583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fed conditions
Study NCT04664842 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Diaphragmatic Stretch Technique
Description: Diaphragmatic stretch technique is an intervention intended to indirectly stretch the diaphragmatic muscle fibers. This will help to decease tension generated by trigger points, normalizing muscle ﬁber length, and improve muscle contraction.
Study NCT04664842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Stretch Technique
Description: Diaphragmatic stretch technique is an intervention intended to indirectly stretch the diaphragmatic muscle fibers. This will help to decease tension generated by trigger points, normalizing muscle ﬁber length, and improve muscle contraction.
Study NCT04664842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercise Training
Description: During diaphragmatic or abdominal breathing training, inhalation will caused diaphragm contract downwards, inflating the lungs. This filling of the lungs pushes the abdominal organs down leading to expansion of the abdomen. Subjects are required to do few repetitions during the intervention.
Study NCT04664842 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Breathing Exercise Training
Description: During diaphragmatic or abdominal breathing training, inhalation will caused diaphragm contract downwards, inflating the lungs. This filling of the lungs pushes the abdominal organs down leading to expansion of the abdomen. Subjects are required to do few repetitions during the intervention.
Study NCT01989065 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: see arm description
Study NCT01989065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: see arm description
Study NCT01989065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: See Arm Description
Study NCT04399109 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCC-COVID mHealth solution
Description: Patients place their index finger in the pulse oximeter to measure their oxygen saturation and pulse rate twice a day, which will take approximately 5 minutes each time. Patients then enter the results into the TCC-COVID app twice daily, and complete a symptom questionnaire via the TCC-COVID app once daily, which will take approximately 5 minutes. The symptom questionnaire was designed specifically for this study. The measurements and information are directly connected to a clinician interface (KIOLA database) which provides the data of all patients in aggregate and an easy to use responsive format with customisable alerts. The alerts identify if the oxygen saturation levels are low or the pulse rate is out of range. The alerts also identify if a measurement has not been completed in a timely manner and the central monitoring service will contact the patient to check on their safety or if they are experiencing any technical issues. The overall duration of participation will be 14 days.
Study NCT03979807 — intervention group
Intervention type: DRUG
Intervention: Olodaterol/Tiotropium Bromide
Description: (Stiolto®) delivered via Respimat inhaler
Study NCT03979807 — intervention group
Intervention type: DRUG
Intervention: Umeclidinium/ Vilanterol
Description: (Anoro®) delivered via Ellipta Inhaler
Study NCT02478866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-9016M
Description: Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg，600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
Study NCT03359330 — intervention group
Intervention type: OTHER
Intervention: Degradable Conduit Small Gap Tublization
Description: Degradable Conduit Small Gap Tublization Repairing Peripheral Nerve Injury
Study NCT04061616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PASIPD-Fr
Description: Fill-out the PASIPD-Fr self questionaire twice (2 completions at a 2-week interval)
Study NCT04303520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19/CD22 CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
Study NCT00367965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: eszopiclone 3 mg
Study NCT00367965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet
Study NCT04303520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d
Study NCT04303520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg/m2/d
Study NCT00652626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Study NCT02092558 — intervention group
Intervention type: DRUG
Intervention: Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution
Study NCT02092558 — intervention group
Intervention type: DRUG
Intervention: cephalosporin with chemotherapeutics
Description: Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months
Study NCT00622180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NBUVB
Description: NBUVB hand foot box
Study NCT00622180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monochromacitc Excimer light
Description: Treatment with Monochromacitc Excimer light
Study NCT04243070 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3-channel Holter ECG recording
Description: 3-channel Holter ECG recording for patients undergoing an EPS
Study NCT04243070 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 12-channel Holter ECG recording
Description: 12-channel Holter ECG recording for patients undergoing a routine follow-up
Study NCT03899168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Tag Popularity
Description: The relative size of treatment tags in a tag cloud was either larger for antidepressant treatments or psychotherapy treatments.
Study NCT03899168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Confidence in Prior Attitudes
Description: Participants thought back of situations in which they were either confident or doubtful about their own knowledge. This should elicit a mindset where participants are more or less confident about their own prior attitudes.
Study NCT03899168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Source Credibility
Description: The source credibility of the community that allegedly collected and labelled the blog posts was either high or low in terms of expertise. Either experts (high credibility) or first semester students (low credibility) did allegedly collect blog posts. This was indicated by banners on top of the navigation platform in the internet browser.
Study NCT01082211 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-Conformal External Beam
Description: Radiation was to be delivered in 2 fractions per day, each of 1.5 Gy, separated by at least six hours, given in 15 consecutive working days to a total of 30 fractions and 45 Gy. Radiation was to be prescribed to the treatment unit isocenter, positioned at the approximate center of the planning target volume.
Study NCT01386138 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education
Description: Receive RBT education and peer-support in a group format.
Study NCT01386138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Receive RBT education and a pro-active counseling method
Study NCT03158480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK immunotherapy
Description: Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients
Study NCT03158480 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DC-CIK immunotherapy
Description: Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients
Study NCT01220388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-lysine
Description: L-lysine, 4,95 G at day : 0,55 G 3 times a day, orally, during meals
Study NCT01220388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, 3 times a day, orally, during meals
Study NCT03835624 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: interleukin 33
Description: serum and synovial fluid samples will be obtained from patients and serum samples from controls to measure interleukin 33 and its relative mRNA expression in peripheral blood mononuclear cells by PCR
Study NCT03268200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: segmental reexamination
Description: segmental reexamination during colonoscopy
Study NCT03822663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Description: The experimental procedure for each athlete includes an acute CAF supplementation in a different-dose crossover regimen in order to assess whether the dose affects the actual physical capacity and discipline-specific exercise performance (doses: 3.0-, 6.0- and 9.0 mg/kg of body mass, respectively). CAF (pure pharmaceutical caffeine) will be administered in the dissolved form. On testing days, the supplements will be taken 70 min before physical and exercise capacity test session. Between the CAF and PLA or a PLA and CAF treatments, a minimum 7-day washout period will be introduced.
Study NCT03822663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: The experimental procedure for each athlete will include PLA supplementation. Placebo will be administered in the dissolved form. On testing days, the PLA will be taken 70 min before physical and exercise capacity test session. Between the PLA and CAF or a CAF and PLA treatments, a minimum 7-day washout period will be introduced.
Study NCT01444859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trenev Trio®/Healthy Trinity®
Description: Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)
Study NCT01497925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: Dosage: 4.5, 9, 18 and 36 mg/m2. Frequency: weekly.
Study NCT02404688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active delta-9-THC
Description: Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes.
Study NCT02404688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: small amount of alcohol (quarter teaspoon), with no THC. Administered over 20 minutes.
Study NCT02404688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: small amount of alcohol (quarter teaspoon), with no THC. Administered over 20 minutes.
Study NCT02404688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Ethanol
Description: Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
Study NCT02404688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: no alcohol, administered for a total of 80 minutes.
Study NCT02404688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: no alcohol, administered for a total of 80 minutes.